Xeltis announced today that it completed enrollment in an EU pivotal trial for aXess, its restorative vascular access conduit ...

Xeltis announced the completion of enrollment in its European Union (EU) pivotal trial for the aXess restorative vascular access ...

Xeltis is currently enrolling up to 140 patients in the aXess US pivotal trial, with Dr. John Lucas III, Surgeon at Lucas Surgical Group, P.A., as the National Principal Investigator. Professor ...

Xeltis BV completed enrollment in the EU pivotal trial for its restorative vascular access conduit, Axess. The prospective study will investigate the patency, safety and performance of Axess in adult ...

Xeltis has hit two milestones for its vascular access conduit, with one coming in the regulatory arena and the other in the device’s clinical journey. The Dutch company shared that the US Food ...